Reference is being made to the stock exchange release from
Arctic Bioscience is pleased to announce that the CTA has been approved in the
Arctic Bioscience is currently in the process of activating the clinical trial sites in the
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
CEO of
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
Jone R. Slinning
CFO of
Mobile: +47 948 75 469
Email: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---clinical-trial-application-for-hro350-phase-iib-approved-in-the-uk,c3696948
(c) 2023 Cision. All rights reserved., source